Compare Cytokinetics Inc (CYTK) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs H2O America — how do they compare? Cytokinetics Inc trades at $62.66 (market cap $8.62B), while H2O America trades at $58.45 (market cap $2.43B). The key difference: Cytokinetics Inc is far larger — about 3.5× H2O America's market cap, and H2O America pays a 3.03% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and H2O America for 40 Days on average.
| CYTK | HTO | |
|---|---|---|
Market Cap | $8.62B | $2.43B |
Volume | 2,594,626 | 593,883 |
Sector | Health | Utilities |
52-Week High | $87.26 | $65.43 |
52-Week Low | $54.76 | $44.44 |
Typical Hold Time | 19 Days | 40 Days |
Enterprise Value | $8.72B | $4.22B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
HTO trades at $57.98, down 0.34% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 12.91% net margin and 6.46% ROE, supported by recent acquisitions in Texas water utilities. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target, representing 15% upside potential from current levels.
The stock offers attractive dividend yield with recent $0.44 dividend declaration, but faces execution risks from acquisition integration and negative cash flow from investing activities. Technical indicators show mixed signals with oversold RSI readings conflicting with bearish moving averages, creating potential entry opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
